Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The company received 1 (One) observation in the Form-483
Zydus receives EIR for the API manufacturing facility at Ankleshwar
This strategic expansion marks a significant step in the company's global growth strategy
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Subscribe To Our Newsletter & Stay Updated